John Diekman Biography and Net Worth

Director of Zai Lab

John D. Diekman, Ph.D., has been our Independent Director since 2017. Dr. Diekman is founding partner of 5AM Ventures, where he has served since 2002. He is chairman of the board of directors of IDEAYA Biosciences, Inc. an oncology target discovery company; director of Cleave Therapeutics, Inc., a cancer therapeutic company; and director of Wildcat Discovery Technologies, Inc., a technology company that discovers materials for energy storage applications; charter trustee of Princeton University; chairman of the board of directors of The Scripps Research Institute; and a member of the advisory board of the Schaeffer Center for Health Policy and Economics at the University of Southern California. During the last five years, Dr. Diekman also served as director of Calibrium LLC, a biopharmaceutical research company focused on diabetes and other metabolic diseases; Cellular Research, Inc., a single-cell genomics startup; and PhaseRx Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children.

Dr. Diekman holds an A.B. in Organic Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.

What is John D. Diekman's net worth?: The estimated net worth of John D. Diekman is at least $1.65 million as of May 5th, 2021. Mr. Diekman owns 62,852 shares of Zai Lab stock worth more than $1,648,608 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Diekman may own. Learn More about John D. Diekman's net worth.
How do I contact John D. Diekman?: The corporate mailing address for Mr. Diekman and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on John D. Diekman's contact information.
Has John D. Diekman been buying or selling shares of Zai Lab?: John D. Diekman has not been actively trading shares of Zai Lab within the last three months. Most recently, John D. Diekman sold 1,000 shares of the business's stock in a transaction on Friday, February 4th. The shares were sold at an average price of $50.17, for a transaction totalling $50,170.00. Learn More on John D. Diekman's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $119,600.00. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 105,597 shares worth more than $2,125,230.82. The most recent insider tranaction occured on August, 16th when insider Joshua L Smiley sold 4,352 shares worth more than $72,547.84. Insiders at Zai Lab own 13.9% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 8/16/2024.

John D. Diekman Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/4/2022	Sell	1,000	$50.17	$50,170.00
11/5/2021	Sell	1,000	$91.65	$91,650.00
8/5/2021	Sell	1,000	$149.50	$149,500.00	61,852
5/5/2021	Sell	1,000	$153.62	$153,620.00	62,852

John D. Diekman Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $26.23

$25.63

$26.77

50 Day Range

MA: $26.28

$20.34

$33.18

2 Week Range

Now: $26.23

$13.48

$36.60

Volume

1,384,654 shs

Average Volume

1,308,194 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>